Biotech decks fail when they’re too scientific for investors and too shallow for experts.
This one had to strike the balance.
The brief
A clinical-stage biotech company developing a multi-application therapeutic molecule needed an investor presentation for venture capital and strategic pharma partners.
The science was strong.
The story needed clarity.
What I built
- Clinical validation and pipeline slides
- Market size and oncology opportunity
- Mechanism of action visual explanations
- Competitive positioning
- Commercialization strategy
- Investor and partnership narrative
Every slide was designed to simplify without dumbing down.
The result
A clean biotech investor deck designed for:
- VC fundraising
- pharma partnerships
- strategic licensing discussions
Scientific credibility remained intact — but investors could finally understand the scale of the opportunity.
Check the Dribbble case study.
Building a biotech or healthtech company?
If investors don’t understand your science quickly, they won’t fund it.
Clarity isn’t optional in biotech pitching.
